Compare BridgeBio Pharma Inc (BBIO) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs The Vita Coco Company Inc — how do they compare? BridgeBio Pharma Inc trades at $84.33 (market cap $16.61B), while The Vita Coco Company Inc trades at $64.26 (market cap $3.63B). The key difference: BridgeBio Pharma Inc is far larger — about 4.6× The Vita Coco Company Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | COCO | |
|---|---|---|
Market Cap | $16.61B | $3.63B |
Sector | Health | Technology |
52-Week High | $90.17 | $84.02 |
52-Week Low | $47.29 | $32.37 |
Enterprise Value | $18.16B | $3.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
